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Soluble ICAM-1 in CSF coincides with the extent of cerebral
damage in patients with severe traumatic brain injury
Abstract
The intercellular adhesion molecule-1 (ICAM-1) expressed by endothelial cells is crucial in promoting
adhesion and transmigration of circulating leukocytes across the blood-brain barrier (BBB). Migrated
immunocompetent cells, in turn, release mediators that stimulate glial and endothelial cells to express
ICAM-1 and release cytokines, possibly sustaining cerebral damage. Following activation, proteolytic
cleavage of membrane-anchored ICAM-1 results in measurable levels of a soluble form, sICAM-1. The
aims of this study were to investigate the changes of sICAM-1 levels in ventricular CSF and serum and
to elucidate the influence of structural brain damage as estimated by computerized tomography (CT) as
well as the extent of BBB dysfunction as calculated by the CSF/serum albumin ratio (QA) in patients
with severe traumatic brain injury (TBI). All investigated parameters revealed two subgroups. Patients
belonging to group A had sICAM-1 levels in CSF above normal range, presented marked cerebral
damage and a disturbance of the BBB (range 0.6-24.7 ng/ml, n = 8). In contrast, patients belonging to
group B had no elevation of sICAM-1 values in CSF (range 0.3-3.9 ng/ml, n = 5; p < 0.017) and showed
minor cerebral damage with an intact BBB in most cases. In addition, overall analysis showed that
sICAM-1 in CSF correlated with the extent of BBB damage as indicated by the QA (r = 0.76; p <
0.001). These results suggest that increased sICAM-1 levels in CSF might depict ongoing immunologic
activation and that sICAM-1 correlates with the extent of tissue and BBB damage. The origin of soluble
ICAM-1 in CSF and its pathophysiologic role after TBI remains to be clarified.
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Traumatic Brain Injury
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ABSTRACT
The intercellular adhesion molecule-1 (ICAM-1) expressed by endothelial cells is crucial in pro-
moting adhesion and transmigration of circulating leukocytes across the blood-brain barrier (BBB).
Migrated immunocompetent cells, in turn, release mediators that stimulate glial and endothelial
cells to express ICAM-1 and release cytokines, possibly sustaining cerebral damage. Following ac-
tivation, proteolytic cleavage of membrane-anchored ICAM-1 results in measurable levels of a sol-
uble form, sICAM-1. The aims of this study were to investigate the changes of sICAM-1 levels in
ventricular CSF and serum and to elucidate the influence of structural brain damage as estimated
by computerized tomography (CT) as well as the extent of BBB dysfunction as calculated by the
CSF/serum albumin ratio (Qa) in patients with severe traumatic brain injury (TBI). All investigated
parameters revealed two subgroups. Patients belonging to group A had sICAM-1 levels in CSF
above normal range, presented marked cerebral damage and a disturbance of the BBB (range
0.6-24.7 ng/ml, n = 8). In contrast, patients belonging to group B had no elevation of sICAM-1 val-
ues in CSF (range 0.3-3.9 ng/ml, n = 5; p < 0.017) and showed minor cerebral damage with an in-
tact BBB in most cases. In addition, overall analysis showed that sICAM-1 in CSF correlated with
the extent of BBB damage as indicated by the QA (r = 0.76; p < 0.001). These results suggest that
increased sICAM-1 levels in CSF might depict ongoing immunologie activation and that sICAM-1
correlates with the extent of tissue and BBB damage. The origin of soluble ICAM-1 in CSF and its
pathophysiologic role after TBI remains to be clarified.
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INTRODUCTION ates leukocyte cell adhesion and antigen-specific T-cell
activation by binding to /^-integrin molecules, such as
The intercellular adhesion molecule-1 (ICAM-1, lymphocyte function-associated molecule-1 (LFA-1,CD54) is expressed on endothelial cells, astrocytes, CD1 la/18) and complement receptor type 3 (Mac-1,
microglia, and B-and T-lymphocytes and is up-regulated CD 1 lb/18), expressed on leukocytes and macrophages
in response to various stimuli (Frohman et al., 1989; (Smith et al., 1989; Diamond et al., 1990; Dustin and
Satoh et al., 1991a; Sobel et al., 1990). ICAM-1 medi- Springer, 1988; Rothlein et al., 1986). Proteolytic cleav-
'Division of Research and 2Division of Trauma Surgery, Department of Surgery, University Hospital Zuerich, Switzerland.
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age of cell-bound ICAM-1 following functional interac-
tion between leukocytes and ICAM-1 results in measur-
able levels of a circulating and soluble protein (sICAM-
1) (Rothlein et al., 1991; Seth et al., 1991).
Under normal conditions, cerebral endothelial cells
show very low constitutive adhesion molecule expres-
sion, and only a few leukocytes and macrophages are
found within the brain because of the impermeability of
the blood-brain barrier (BBB) to resting white blood cells
(Weckerle, 1993). Transient adhesion, transendothelial
and subendothelial migration of leukocytes are promoted
by adhesion molecules and request the participation of
signalling mediators such as platelet activating factor(PAF) or interleukin (IL)-8 released by neutrophils
(Abelda et al., 1994; Carlos and Harlan, 1994; Rössler et
al., 1992; Zimmermann et al., 1992). Leukocytes trans-
migrated into the brain release pro-inflammatory cy-
tokines such as IL-1, IL-6, interferon (IFN)--y, and tumor
necrosis factor (TNF)-a, which, in turn, up-regulate the
expression of ICAM-1 on various cell types (Aloisi et al.,
1992; Fabry et al., 1992; Frohman et al., 1989; Satoh et
al., 1991b) and produce cytotoxic agents such as gluta-
mate, oxygen radicals, and proteolytic enzymes (Zhuang
et al., 1993). The release of pro-inflammatory cytokines
(Kossmann et al., 1996, 1997; Morganti-Kossmann et al.,
1997) and neurotoxins (e.g., glutamate) within the brain
is thought to aggravate BBB damage, leading to vaso-
genic and cytotoxic brain edema formation (Greenwood,
1991; Weckerle, 1993), possibly resulting in a self-sus-
taining vicious circle (Cross et al., 1991; Staub et al.,
1996).
Various experimental models of ischemia revealed a
correlation between the amount of accumulated granulo-
cytes, increased cortical water content, and elevated in-
tracranial pressure (Biagas et al., 1992; Schoettle et al.,
1990; Zhuang et al., 1993), reflecting the contribution of
leukocytes to secondary brain damage. The administra-
tion of specific antibodies directed against ICAM-1 sig-
nificantly reduced neutrophil accumulation, edema for-
mation, infarction size, and neurologic damage after
transient middle cerebral artery occlusion in rats (Bowes
et al., 1993; Matsuo et al., 1994; Zhang et al., 1994). In
ICAM-1 knockout mice, infarct volume and neurologic
deficits were markedly reduced after focal cerebral is-
chemia, and survival was significantly prolonged in com-
parison with ICAM-1 +/+ animals (Connolly et al.,
1996). An increased expression of ICAM-1 within cere-
bral parenchyma may lead to release of the soluble form
of ICAM-1 in CSF as a result of proteolytic cleavage,
possibly reflecting ongoing posttraumatic immunoacti-
vation.
The aims of this study were to investigate the alter-
ations of sICAM-1 levels in CSF and serum in patients
following severe traumatic brain injury (TBI) and to elu-
cidate whether or not sICAM-1 correlates with the extent
of brain damage and with the alterations of BBB func-
tion as calculated by the CSF/serum albumin ratio (QA).
MATERIALS AND METHODS
Patients
A total of 13 patients (range 16-67 years; mean 37.5
years; 3 females, 10 males) were included in this study.
The patients were treated according to a standardized pro-
tocol at the Division of Trauma Surgery at the Univer-
sity Hospital Zürich, Switzerland (Stocker et al., 1995).
All patients suffered from severe TBI and had a Glasgow
coma score (GCS) ^9 upon admission. Patients with tho-
racic, abdominal, pelvic, or spinal cord injuries were ex-
cluded. After clinical and computerized tomography (CT)
evaluation, intraventricular catheters were implanted to
monitor intracranial pressure (ICP) and to therapeutically
drain CSF. Control CSF samples were taken from eight
patients without TBI following either diagnostic lumbar
puncture without neuropathology or ventriculoperitoneal
shunt. The study protocol was approved by the Univer-
sity Hospital Medical Ethics Board. The patients were
clinically evaluated according to the Glasgow outcome
score (GOS) (Jennett and Bond, 1975), a numeric scale
that describes the neurologic outcome of patients, as-
sessed 3 and 6 months after TBI (GOS 1 = death, 2 =
persistent vegetative state, 3 = severe disability, 4 =
moderate disability, 5 = good recovery).
CSF and Serum Sampling
Drained CSF, collected on ice over 24 h, and arterial
serum samples drawn once daily were centrifuged at 1000
rpm for 10 min at 4°C and frozen at -70°C until further
analysis.
Analysis of Soluble ICAM-1
Soluble ICAM-1 was analyzed by sandwich enzyme-
linked immunosorbent assay (ELISA) using a commer-
cial kit (R&D Systems, Abingdon, UK). The standard
curve was linear from 0 to 46 ng/ml, with a lower de-
tection limit at 0.35 ng/ml. Absorbance was measured at
450 nm with a correction wavelength of 620 nm using a
microplate reader (Dynatech Laboratories Inc., Alexan-
dria, MD).
Evaluation of Brain Damage According to
Computerized Tomography (CT)
CT scans were evaluated by an independent blinded
investigator. The extent of cerebral damage was assesed
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by calculating the size of contusions and pericontusional
edema formation, applying the mathematical formula for
elliptoid structures [volume = 4/3ir X a X b X c (cm3)]
and by measuring the distance from the ventricular sys-
tem in centimeters.
Blood-Brain Barrier Damage
The extent of BBB dysfunction was estimated by cal-
culating the CSF/serum albumin ratio (Qa) daily. The
BBB was defined as intact with QA levels up to 0.007.
The disturbance of the BBB permeability was rated mild,
moderate, and severe, with QA-values ranging from
0.007-0.01, 0.01-0.02, and above 0.02, respectively
(Reiber and Felgenhauer, 1987). CSF and serum albumin
were measured by automatized laser photometry (BNA
Automat, Behringwerke, Marburg a.L., Germany).
Statistical Analysis
Statistical analysis was performed using the Mann-
Whitney U-test with a modified Bonferroni correction for
repeated measurements and linear regression analysis.
The upper normal limit of sICAM-l was defined as mean
plus three standard deviations of control values. Results
are given as mean ± standard error of the mean (SEM).
Differences were considered significant at/? < 0.05.
RESULTS
Soluble ICAM-1 in CSF and Serum
Soluble ICAM-1 was measured daily by ELISA in CSF
and serum of 13 patients following TBI for a time period
up to 19 days. Table 1 summarizes the epidemiological
data as well as the means and ranges of sICAM-1 and
Qa for each individual.
This analysis revealed two subgroups of patients for
sICAM-1 values in CSF. In order to compare the groups
statistically, we used the mean of all sICAM-1 measure-
ments of each patient for up to 19 days after trauma and
calculated the average of the means for each group. The
differences were analyzed by the nonparametric Mann-
Whitney U-test for all parameters. Patients belonging to
group A had significantly higher sICAM-1 values in CSF
compared with those in group B (group A, range 0.6-24.7
ng/ml; average of the mean ± SEM 7.15 ± 0.83, n = 8;
group B, range 0.3-3.9 ng/ml, average of the mean
1.42 ± 0.23, n = 5; p = 0.003). In group B, CSF
sICAM-1 levels were comparable with control values
(control CSF, range 0.27-1.97; mean 0.9 ± 0.2 ng/ml).
With regard to the kinetics of sICAM-1, it appeared that
CSF sICAM-1 levels increased within 24 h after trauma
in group A, remained elevated during 10 days, and de-
creased gradually over time, while concentrations of
sICAM-1 in group B remained within the normal range
during the entire study period (Table 2). The kinetics of
sICAM-1 in CSF and serum are shown for both patient
groups in Fig. 1.
Serum sICAM-1 concentrations were nearly 100-fold
higher than corresponding CSF values. Contrary to
changes in CSF, serum levels were not significantly ele-
vated until day 9 in both groups. Overall analysis showed
no differences between groups A and B during the in-
vestigated time period after trauma (group A, range
121.2-822.9 ng/ml, average of the mean 414.6 ± 21.37;
group B, range 118.2-890.2 ng/ml, average of the mean
354.3 ± 37.45, p = 0.24). However, the kinetics of
sICAM-1 in serum showed an elevation in group A at
Table 1. Epidemiological Data of 13 Traumatic Brain Injury Patients According to Groups A and B
Patient No. Sex Age Group
sICAM CSF
(ng/ml)
sICAM Serum
(ng/ml) Albumin Quotient (QA) GOS
1
2
3
4
5
6
7
8
9
10
11
12
13
m
m
m
m
ni
f
m
ni
m
f
m
m
f
67
48
55
26
31
31
53
59
19
23
41
16
18
A
A
A
A
A
A
A
A
B
B
B
B
B
5.0
8.3
7.2
10.9
9.3
3.6
6.4
6.6
1.2
2.3
1.2
0.9
1.6
1.6
5.8
4.2
4.2
5.5
1.7
3.8
2.6
0.5
0.9
0.3
0.3
0.7
392.0
385.4
344.7
488.9
439.4
415.1
349.3
507.3
394.9
299.8
495.4
250.3
360.0
38.1
175.2
125.6
89.3
68.4
29.7
156.3
202.9
30.6
66.2
233.2
46.9
57.9
0.0198
0.0267
0.0242
0.0242
0.0100
0.0214
0.0114
0.0127
0.0036
0.0041
0.0032
0.0018
0.0034
0.011
0.021
0.016
0.005
0.018
0.007
0.012
0.005
0.001
0.004
0.0012
0.0003
0.0014
Geometric means
(GOS) are given.
SD of soluble ICAM-1 (ng/ml) in CSF and serum, albumin quotient (Qa), and the Glasgow outcome scale
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Table 2. Kinetics of sICAM-1
Day I Day 9 Day 18
Group A 9.8 ± 3.6 9.5 ±1.6 4.4 ± 1.1
CSF
Group B 1.1 ± 0.2 1.9 ± 0.5 1.3 ± 0.1
CSF
Group A 286.9 ± 27.3 514.4 ± 58.7 509.0 ± 107.0
serum
Group B 298.0 ± 42.5 476.5 ± 141.5 343.9 ± 25.1
serum
Levels of sICAM-1 in CSF decreased over time in group A,
whereas sICAM-1 values in group B remained unchanged. In
serum, sICAM-1 values showed an elevation in group A at day
9 persisting up to the end of the study period, whereas in group
B, there was only a transient elevation between days 9 and 13,
followed by a rapid decrease to normal ranges.
day 9, persisting to the end of the study period, whereas
in group B there was only a transient elevation between
days 9 and 13, followed by a rapid decrease to normal
ranges (Fig. 1).
In order to further determine whether higher sICAM-
1 levels in CSF may depend on intrathecal release or on
changes in serum, a CSF/serum ratio for sICAM-1 (Qsl-
CAM-1) was assessed as previously shown for patients
with neurologic diseases (Rieckmann et al., 1993). This
calculation showed significantly higher QsICAM-1 val-
ues in group A compared with group B (QsICAM-1:
group A, range 0.0031-0.097, average of the mean
0.019 ± 0.002; group B, range 0.0009-0.013, average
of the mean 0.0045 ± 0.001; p = 0.004). In addition,
the fluctuations of sICAM-1 in CSF occured indepen-
dently from those in serum in all patients (data not
shown).
BBB Damage
Significantly elevated CSF sICAM-1 levels in group
A coincided with a more disturbed BBB as estimated by
Qa compared with patients (group B) with low CSF
sICAM-1 values (group A, QA range 0.002-0.088, aver-
age of the mean 0.017 ± 0.002; group B, range
0.0014-0.019, average of the mean 0.003 ± 0.0004; p =
0.0034). Patients in group A showed a severe BBB dam-
age during the first posttraumatic days, changing over the
following days to a moderately disturbed BBB and nearly
normalizing within the third week. In group B, the QA-
c
<
o
Group A n-
1 23456789 1011 12 1314 15 16 17 18 19 days
6668788887777543343
Group B n= 22545454554544454454
FIG. 1. Levels of soluble intercellular adhesion molecule-1 (sICAM-1) in cerebrospinal fluid (CSF) and serum following trau-
matic brain injury (TBI). Changes of sICAM-1 in CSF and serum of patients suffering from severe TBI are presented as group
A (T = high sICAM-1 levels) and group B (A = low sICAM-1 levels). Results are given as geometric mean ± SEM. In group
B, the size of the symbol is larger than the SEM at most time points. The number of samples (ri) daily available for analysis for
each patient group is given at the bottom of the figure. The gray area represents the normal range of sICAM-1 levels in both flu-
ids and was calculated as mean + 3SD of control samples.
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FIG. 2. Levels of soluble intercellular adhesion molecule-1 (sICAM-1) in cerebrospinal fluid (CSF) correlate with blood-brain
barrier (BBB) damage. Linear regression analysis reveals mutual dependency between sICAM-1 in CSF and the extent of BBB
damage as assessed by the CSF/serum albumin ratio (QA) in group A (O) and group B (•) (r = 0.76, p < 0.001). Values lo-
cated within the top circle depict increased CSF sICAM-1 concentrations in patients with a mildly to moderately disturbed BBB.
values remained normal or mildly elevated during the en-
tire study period (data not shown).
In order to analyze the dependency of sICAM-1 lev-
els in CSF on the dysfunction of the BBB, linear regres-
sion analysis of sICAM-1 in CSF and QA values of all
patients was performed (Fig. 2). This analysis showed a
correlation between the levels of sICAM-1 in CSF and
the Qa (r = 0.76, p < 0.001). However, some patients
had sICAM-1 values in CSF above the normal range, al-
though the BBB was only mildly to moderately disturbed
(Fig. 2).
Extent of Cerebral Damage as Estimated by CT
Cranial CT scans were evaluated upon admission and
on days 1, 5, and 14 after injury. Patients with higher
CSF sICAM-1 levels (group A) showed larger structural
lesions, represented as contusions, with a gradual pro-
gression of perifocal edema and a smaller distance to the
ventricular system. To the contrary, patients with low
CSF sICAM-1 values (group B) showed small contu-
sions, and the perifocal edema did not expand toward the
ventricular system in any patient (Fig. 3).
Levels of sICAM-1 and the Glasgow Outcome
Scale (GOS)
The GOS was determined for all patients 3 and 6
months after traums. Patients in group A recovered to dif-
ferent extents, having GOS values between 1 and 5 [GOS
1 (n = 1), GOS 3, (n = 3), GOS 4 (n = 3), GOS 5 (n =
1)]. Interestingly, all patients belonging to group B
showed a good recovery with only minor neurologic
deficits (GOS = 5, n = 5, Table 1).
Influence of Intracranial Pressure (ICP) and
Cerebral Perfusion Pressure (CPP)
No significant differences were observed in the two
groups in regard to the ICP (group A, maximum ICP
range 6-69 mm Hg, average of the mean 20.2 ±1.3 mm
Hg; group B, maximum ICP range 11^3 mm Hg, aver-
age of the mean 20.5 ± 1.1 mm Hg, p = 0.88) and CPP
(group A, range 73.5-115.8 mm Hg, average of the mean
72.5 ± 2.2; group B, range 66-107.2 mm Hg, average of
the mean 68.9 ± 2.3, p = 0.39).
DISCUSSION
The release of sICAM-1 was investigated in CSF and
serum samples of patients with severe TBI for up to 19
days after trauma. Analysis of the data revealed that in-
crease of sICAM-1 values in CSF is associated with the
presence of cerebral contusions as well as with an unfa-
vorable outcome. In addition, a significant correlation be-
tween the levels of sICAM-1 in CSF and the disturbance
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group A group B
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FIG. 3. Soluble intercellular adhesion molecule-1 (sICAM-1) levels are associated with computed tomography (CT) scan pat-
tern. CT scans at days 0, 1,5, and 14 were analyzed with respect to (A) size of cerebral contusion (cm3), (B) pericontusional
edema, and (C) distance from the ventricular system, and grouped according to the levels of sICAM-1 in cerebrospinal fluid(CSF), as described in Materials and Methods. Patients with high sICAM-1 values in CSF (group A) show larger contusion sizes
decreasing over time, and a progressive perifocal edema with only a small distance to the ventricular system. Patients with low
CSF sICAM-1 values (group B) show small contusion volumes, unchanged perifocal edema, and a large distance to the ventric-
ular system.
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FIG. 3. Continued.
of the BBB was also shown. However, it is not clear from
this study whether increased the sICAM-1 found in CSF
originates from plasma via translocation through the BBB
or is derived from intracerebral production.
Increased sICAM-1 values in CSF may result from en-
hanced posttraumatic expression of ICAM-1 on activated
cells combined with proteolytic cleavage of the mem-
brane-bound form (Rothlein et al., 1991; Seth et al., 1991;
Budnik et al., 1996; Rieckmann et al., 1995a) or from a
sustained cleavage of constitutively expressed mem-
brane-bound ICAM-1. Apart from enzymatic cleavage,
the soluble form of ICAM-1 is also believed to be pro-
duced anew, since two distinct mRNAs, one for mem-
brane-bound ICAM-1 and one for soluble ICAM-1, have
been demonstrated (Simmons et al., 1988; Staunton et al.,
1989; Wakatsuki et al., 1995). sICAM-1 in CSF may
originate from cerebral endothelial cells and astrocytes,
since these cell-types were shown to express (ICAM-1 in
vitro (Frohman et al., 1989; Satoh et al., 1991a; Rieck-
mann et al., 1995a) and in vivo (Cannella et al., 1995;
Sharief et al., 1993; Sobel et al., 1990; Shibayama et al.,
1996; Isaksson et al., 1997).
Since serum levels of sICAM-1 are up to 100-fold
higher than those in CSF, a damaged BBB is required for
passive translocation and penetration of these molecules
into the central nervous system (CNS). The simultaneous
and significant increase of Qa values and elevated
sICAM-1 levels of patients belonging to group A under-
line the importance of diffusion processes through the
BBB, as already discussed for inflammatory neurologic
diseases (Jander et al., 1993; Sharief et al., 1993; Rieck-
mann et al., 1993). However, variations in serum sICAM-
1-levels did not correspond to changes in CSF. Compa-
rable levels of serum sICAM-1 were found in both patient
groups, whereas CSF sICAM-1 values were up to 10
times higher in group A than in group B, thus resulting
in a higher QsICAM-1 in group A as well. The QsICAM-
1 values found in group A were comparable with levels
reported in patients with inflammatory diseases of the
CNS (Rieckmann et al., 1993). It remains to be clarified
whether sICAM-1 in CSF is elevated because of in-
trathecal production or because of increased leakage
across the BBB.
Apart from traumatically induced damage of cerebral
endothelial cells with subsequent passive translocation of
serum sICAM-1, it is believed that trauma-related shear-
ing of endothelial cells in itself induces enhanced ex-
pression of ICAM-1 (Nagel et al., 1994). Supportive of
this hypothesis is the finding that a few patients included
in this study showed elevated sICAM-1 values with
nearly normal BBB function (Fig. 2), suggesting possi-
ble intrathecal release of sICAM-1. A slight dysfunction
of the BBB may not be sufficient for a passive leakage
of sICAM-1 from the periphery into CSF, since the mol-
ecular weight of sICAM-1 is greater than that of albu-
min (80-120 kD and 60 kD, respectively). Independently
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from its origin, sICAM-1 present in the CNS may affect
the function of the BBB, inducing the release of cytokines
and neurotoxic factors by activated leukocytes (Sharief
et al., 1993; Weckerle et al., 1993). The exact origin of
sICAM-1 in CSF, however, remains to be elucidated.
Although the Qa may only give a reference for the true
BBB, it was used, since we hypothetize that the increased
albumin concentration in CSF derives from the contused
tissue and reaches the ventricular system as previously
described (Duvdevani et al., 1995; Önal et al., 1997). The
course of Qa levels in the CSF of patients with TBI re-
flects the sICAM-1 pattern, showing an elevation during
the first days, followed by a significant decrease by the
end of the second week (data not shown). The rise of
sICAM-1 and albumin in CSF is likely influenced by the
underlying BBB damage, while clearance of these mol-
ecules represents a more complex phenomenon. For al-
bumin, animal studies investigating the restoration pro-
file of contusion and ischémie injury revealed albumin to
persist within the extracellular space at the damaged area
for up to 10 days prior to removal (Baldwin et al., 1996;
Kuroiwa et al., 1985). Apart from glial and/or neuronal
uptake (Tengvar and Ollson, 1982; Liu and Sturner, 1988;
Hoshino et al., 1996), a reverse vesicular transport from
the extracellular space to blood via transendothelial pas-
sage may also occur (Vorbrodt et al., 1987). Removal of
extravasated proteins is thought to mainly result from
pressure-driven bulk flow into the adjacent ventricular
system (Rosenberg et al., 1980; Ohata et al., 1990) and
the subarachnoid space (Ohata et al., 1992). Similar
mechanisms for sICAM-1 clearance might be anticipated
but require further investigation.
The levels of sICAM-1 in CSF correlated with the ex-
tent of brain damage and the clinical outcome. Higher
sICAM-1 levels in CSF were found in patients with per-
ifocal damage, progressing over time and reaching the
ventricular system, compared with those with smaller le-
sions and stable perifocal edema.
Interestingly, patients with smaller structural lesions
and lower sICAM-1 levels in the CSF had a good out-
come, as determined by the GOS of 5, whereas patients
with moderate or unfavorable outcome had elevated
sICAM-1 levels and larger brain lesions combined with
progressive edema. Although sICAM-1 may reflect the
degree of tissue damage and the resulting immunologie
response, it cannot be considered a prognostic marker,
since the remaining half of the patients with high sICAM-
1 still had a moderate to good outcome. The lack of dif-
ferences for ICP and CPP recorded every hour in the two
different groups is most likely due to therapeutic influ-
ences, since ICP was lowered by CSF drainage and CPP
was kept above 70 mm Hg, according to the treatment
protocol (Stocker et al., 1995). Analysis of sICAM-1 only
once a day, as performed in the present study, cannot ac-
curately reveal possible fluctuations within 24 h.
While the function of membrane-bound ICAM-1 in
attracting and binding circulating immunocompetent
cells has been identified, the physiologic role of the sol-
uble form has not been fully understood. The circulat-
ing and soluble form of ICAM-1 is believed to play a
pivotal role in the local regulation of adhesion and de-
adhesion of leukocytes binding to endothelial cells(Rieckmann et al., 1995b). Furthermore, sICAM-1
could possibly bind to circulating leukocytes within the
next proximity or at a distance from the actual site of
tissue damage and consequently antagonize the ICAM-
1 interaction to its ligand LFA-1, expressed on leuko-
cytes (Meyer et al., 1995). Thus, sICAM-1 may possi-
bly attenuate the extent of attraction, binding, and
activation of leukocytes therefore preventing excessive
migration of these cells and tissue damage (Gearing et
al., 1992; Rothlein et al., 1991).
Irrespective of its potential immunologie function,
analysis of sICAM-1 in CSF may facilitate early diag-
nosis of inflammatory and immunologie response within
traumatized brain parenchyma, since ICAM-1 is consid-
ered an early marker of immune activation and response
(Diamond et al., 1990; Seth et al., 1991).
To date, possible therapeutic interventions in patients
with TBI are directed against resident membrane-bound
ICAM-1 in order to minimize secondary brain damage.
In animal models of ischémie brain injury, antibodies di-
rected against ICAM-1 reduced neurologic deficits
(Bowes et al., 1993; Matsuo et al., 1994; Zhang et al.,
1994). In humans, methylxanthine derivatives such as
pentoxifylline have been shown to successfully modulate
the immune system by attenuating the release of pro-in-
flammatory cytokines and reducing the expression of
membrane-bound adhesion molecules (Mandi et al.,
1995; Rieckmann et al., 1996). However, further detailed
investigation is required to test the clinical application of
these drugs in patients suffering from severe TBI.
In conclusion, sICAM-1 may reflect an ongoing in-
flammatory response within the CNS and may depend on
the magnitude of damaged cerebral tissue in patients with
TBI. However, the cellular origin of sICAM-1 in CSF as
well as the mechanism regulating intrathecal elevation of
sICAM-1 following TBI (cleavage, anew synthesis) re-
main to be elucidated.
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